KRTAP9 Activators
KRTAP9 activators are chemical compounds that can increase the functional activity of KRTAP9, a protein known to be regulated by ion transport and cyclic AMP-mediated pathways. Tetrodotoxin, a sodium channel blocker, and Minoxidil, a potassium channel opener, can enhance KRTAP9 activity by increasing the demand for proteins involved in sodium and potassium ion transport. Forskolin, an activator of adenylyl cyclase, and IBMX, a non-specific inhibitor of phosphodiesterases, can enhance KRTAP9 activity by increasing the levels of cyclic AMP, a signaling molecule whose pathways involve KRTAP9.
In the context of calcium-mediated signaling, Verapamil, an L-type calcium channel blocker, Nifedipine, a calcium channel blocker, Cyclopiazonic Acid, a SERCA inhibitor, and Thapsigargin, another SERCA inhibitor, enhance KRTAP9 activity by modulating calcium levels. Ouabain, an inhibitor of the sodium-potassium pump, enhances the need for proteins like KRTAP9 that are involved in sodium and potassium transport. BAY K8644, a calcium channel activator, and Capsaicin, a vanilloid receptor agonist, enhance KRTAP9 activity by increasing intracellular calcium levels. Prostaglandin E2, involved in cyclic AMP-mediated signaling, can enhance KRTAP9 activity through increased signaling in these pathways. Therefore, by understanding how each of these chemicals influence specific biochemical or cellular pathways, we canenhance our understanding of how they may lead to increased functional activity of KRTAP9.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Minoxidil (U-10858) | 38304-91-5 | sc-200984 sc-200984A | 100 mg 1 g | $69.00 $351.00 | ||
Minoxidil is a potassium channel opener. KRTAP9 is also involved in regulating potassium ion transport, therefore, minoxidil can enhance KRTAP9 activity by increasing the need for potassium transport. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylyl cyclase, which increases levels of cyclic AMP. KRTAP9 is known to be involved in signaling pathways mediated by cyclic AMP, hence, increased levels of cyclic AMP can lead to enhanced KRTAP9 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which degrade cyclic AMP. Increased levels of cyclic AMP can enhance KRTAP9 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is an L-type calcium channel blocker. By modulating calcium levels, Verapamil can enhance KRTAP9 activity as the protein has known associations with calcium-mediated signaling pathways. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker that influences calcium availability. By modulating calcium levels, Nifedipine can indirectly enhance KRTAP9 activity. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain inhibits the sodium-potassium pump, enhancing the need for proteins involved in sodium and potassium transport, like KRTAP9. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic Acid is a SERCA inhibitor, which enhances cytosolic calcium levels. KRTAP9 activity is influenced by calcium levels, and the increased cytosolic calcium can lead to enhanced KRTAP9 activity. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
BAY K8644 is a calcium channel activator that can enhance KRTAP9 activity by increasing intracellular calcium levels. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 is involved in cyclic AMP-mediated signaling. As KRTAP9 is known to be involved in these pathways, enhancing the signaling can lead to increased KRTAP9 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA inhibitor, which enhances cytosolic calcium levels. KRTAP9 activity is influenced by calcium levels, and the increased cytosolic calcium can lead to enhanced KRTAP9 activity. | ||||||